- Home
- ADVM vs GEG Comparison
ADVM vs GEG Comparison
Compare ADVM & GEG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADVM
- GEG
- Stock Information
- Founded
- ADVM 2006
- GEG 1994
- Country
- ADVM United States
- GEG United States
- Employees
- ADVM N/A
- GEG N/A
- Industry
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- GEG Computer Software: Prepackaged Software
- Sector
- ADVM Health Care
- GEG Technology
- Exchange
- ADVM Nasdaq
- GEG Nasdaq
- Market Cap
- ADVM 59.5M
- GEG 54.7M
- IPO Year
- ADVM 2014
- GEG N/A
- Fundamental
- Price
- ADVM $2.81
- GEG $1.90
- Analyst Decision
- ADVM Strong Buy
- GEG
- Analyst Count
- ADVM 5
- GEG 0
- Target Price
- ADVM $26.60
- GEG N/A
- AVG Volume (30 Days)
- ADVM 517.4K
- GEG 7.1K
- Earning Date
- ADVM 05-20-2025
- GEG 05-07-2025
- Dividend Yield
- ADVM N/A
- GEG N/A
- EPS Growth
- ADVM N/A
- GEG N/A
- EPS
- ADVM N/A
- GEG N/A
- Revenue
- ADVM $1,000,000.00
- GEG $19,626,000.00
- Revenue This Year
- ADVM N/A
- GEG N/A
- Revenue Next Year
- ADVM $42.58
- GEG N/A
- P/E Ratio
- ADVM N/A
- GEG N/A
- Revenue Growth
- ADVM N/A
- GEG 64.34
- 52 Week Low
- ADVM $2.64
- GEG $1.70
- 52 Week High
- ADVM $10.84
- GEG $2.04
- Technical
- Relative Strength Index (RSI)
- ADVM 38.23
- GEG 48.45
- Support Level
- ADVM $2.64
- GEG $1.76
- Resistance Level
- ADVM $3.64
- GEG $1.98
- Average True Range (ATR)
- ADVM 0.32
- GEG 0.03
- MACD
- ADVM 0.04
- GEG -0.00
- Stochastic Oscillator
- ADVM 17.00
- GEG 20.00
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
About GEG Great Elm Group Inc.
Great Elm Group Inc operates as an alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. Along with its subsidiaries, it manages Great Elm Capital Corp, a publicly traded business development company, and Monomoy Properties REIT, LLC, an industrial-focused real estate investment trust, in addition to other investments.